Pts With Hep C Virus Infection-Related Cryoglobulinemia
30%nausea and abdominal pain
20%Urinary frequency and/or dysuria
This histogram enumerates side effects from a completed 2019 Phase 2 & 3 trial (NCT02825212) in the Pts With Hep C Virus Infection-Related Cryoglobulinemia ARM group. Side effects include: Increased fatigue with 40%, nausea and abdominal pain with 30%, Urinary frequency and/or dysuria with 20%, Herpes Zoster with 10%.
1 Treatment Group
1 of 1
20 Total Participants · 1 Treatment Group
Primary Treatment: Epclusa · No Placebo Group · Phase 2
Experimental Group · 1 Intervention: Epclusa · Intervention Types: Drug
Drug Approval Stage
How many patients have taken this drug
Screening: ~3 weeks
Reporting: 1 year
Who is running the clinical trial?
Baylor Research InstituteLead Sponsor
188 Previous Clinical Trials
186,203 Total Patients Enrolled
6 Trials studying Heart Failure
2,038 Patients Enrolled for Heart Failure
Shelley Hall, MD, FACC, FHFSAStudy ChairBaylor Health Care System
1 Previous Clinical Trials
50 Total Patients Enrolled
Shelley A Hall, MD, FACC, FHFSAStudy ChairBaylor University Medical Center/ Baylor Scott & White Research Institute
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
How old are they?
18 - 65
What site did they apply to?
Baylor University Medical Center
What portion of applicants met pre-screening criteria?